SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about slowing growth, content quality and competition; recent leadership changes and layoffs add to the debate. Bulls see pessimism as overdone, while bears expect further weakness, leaving sentiment sharply divided ahead of the report.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Heavy buying and a sharp rebound have fueled speculation about a potential buyout or imminent company news, but neither has been confirmed. The main catalyst in discussion is the Phase 3 REGAL trials pending final analysis after the last disclosed count of 78 of 80 events; bullish traders read the CEOs optimistic anniversary post as encouraging, while skeptics point to the lack of new trial news and caution that the move may reflect trading activity.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is largely tied to anticipation of the detailed Phase 3 melanoma cancer-vaccine results with Merck at ESMO, after positive topline results sparked a major revaluation. Traders are split between momentum-driven optimism about the broader oncology platform and concerns that expectations and valuation are stretched, with some anticipating a sell-the-news pullback.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound above recent technical levels has traders discussing a possible breakout and short covering, though no specific new catalyst is confirmed. Bulls are also anticipating DM1 and FSHD siRNA readouts, while some caution that the move may reflect broader biotech strength or prove temporary.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid broader concerns about neocloud funding, debt, and whether AI infrastructure spending will generate adequate returns; co-CEO Daniel Roberts comments that the data centers were cash-funded and customer prepayments help cover GPU costs are being cited as reassurance. Traders are split between viewing the selloff as an oversold buying opportunity and expecting further downside, with many frustrated that IREN has lagged peers.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

ADAs weak, range-bound trading and exposure to broader crypto-market selling dominate the discussion, with many traders frustrated by failed rallies and warning of more downside. Others view the pullback as consolidation and say they are accumulating or holding, while watching technical resistance and Bitcoins direction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM shares are under pressure after a quarterly earnings beat failed to offset a narrowed full-year profit outlook that left the midpoint unchanged; weaker U.S. sales and market share also weighed on the reaction. Traders are split between viewing the selloff as overdone given stronger cash-flow guidance and a new buyback, and focusing on the lack of a higher profit outlook.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly beat and raised 2026 outlook are being overshadowed by a sharp selloff. Traders debate whether it is a sell-the-news reaction after expectations ran high or a response to rising costs, weaker cash conversion and an insurance loss, while some point to strong orders as evidence demand remains robust.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention alongside analyst upgrades. Traders are divided over the modest placebo-adjusted symptom improvement and concerns about discontinuations and agitation, with some viewing the data as a positive proof of concept and others arguing the rally may fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp has driven the sharp share move, with traders viewing the cash sale as a balance-sheet and strategic reset. The community is split between bullish momentum and concern that divesting a revenue-generating unit could leave the remaining business smaller and debt pressures unresolved.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for...

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

BioMarin Appoints Cara Bauer as Chief People Officer

BioMarin Appoints Cara Bauer as Chief People Officer BioMarin Appoints Cara Bauer as Chief People OfficerPR NewswireSAN RAFAEL, Calif., Oct. 5, 2026Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology IndustriesAppointment Effective Oct. 5...

BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual Congress

BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual Congress BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual CongressPR...

FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug

AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of DirectorsPR NewswireSAN RAFAEL, Calif., Sept...

BioMarin Reports Positive Phase 3 Results For VOXZOGO

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) on Wednesday announced positive Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia, with the study meeting its primary endpoint and all secondary efficacy endpoints...

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Biomarin Pharmaceutical Inc. - Registered Shares

RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout 

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Martin Shkreli called RARE stock “very cheap” and said BioMarin and other rare-disease drugmakers should explore acquiring Ultragenyx.</li><li>RARE stock's selloff followed the failure of Apazunersen in a Phase 3 Angelman syndrome trial, where the drug missed both its primary and secondary endpoints.</li><li>Analysts said the investment case now depends on commercial execution, margin expansion, and upcoming pipeline catalysts.</li></ul><p>Shares of Ultragenyx Pharmaceutical (RARE) suffered their worst trading day on record and closed at an all-time low on Thursday after its Angelman syndrome treatment failed a key trial, prompting sweeping Wall Street target cuts and takeover speculation from former pharma executive Martin Shkreli.</p><p><a href="https://stocktwits.com/symbol/RARE">RARE stock</a> plunged about 44% to $14.85 on Thursday, wiping out nearly half its value in one session.</p><h2 class="st-heading-2"><strong>Shkreli Floats BioMarin Buyout&nbsp;</strong></h2><p>“$RARE is very cheap,” Shkreli&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2095490113857851515">said on X</a>. He argued that BioMarin Pharmaceutical (BMRN) and other rare-disease companies “should explore buying the company.” Shkreli, widely known as “Pharma Bro,” also claimed that the setback was foreseeable, saying “everyone and their brother with three months of med school/Shkreli training knew this trial would fail.”</p><p>BioMarin and Ultragenyx both develop and commercialize treatments for genetically defined rare diseases, with overlap in metabolic disorders, enzyme-replacement therapies, gene therapy and the specialist physicians they serve.&nbsp;</p><p>Ultragenyx shares crashed after its Phase 3 Aspire trial of Apazunersen, formerly GTX-102, failed both its primary and secondary endpoints. Patients receiving the drug showed no meaningful improvement over the control group in cognition or across a broader measure of Angelman symptoms.&nbsp;</p><p>Apazunersen was designed to activate a normally silent copy of the UBE3A gene. Angelman syndrome is a rare genetic brain disorder that can cause cognitive and movement impairments, seizures, balance problems and severe speech limitations. Ultragenyx estimates it affects about 60,000 people in accessible markets, with no approved treatment for its underlying cause.&nbsp;</p><p>The drug’s safety profile remained consistent with its Phase 1/2 program, but Ultragenyx said it will now assess the program’s future and implement “significant expense reductions.”&nbsp; The company said it will refocus on its expanding commercial portfolio, including recently approved Genglycos for glycogen storage disease type Ia, the potential approval of UX111 for Sanfilippo syndrome and geographic expansion of existing products.&nbsp;</p><h2 class="st-heading-2"><strong>Wall Street Slashes RARE Targets&nbsp;</strong></h2><p>Wall Street stripped the Angelman program from valuation models after the failure. RBC said the lack of numerical disclosure and limited positive framing suggested the drug may have produced no efficacy signal, while cautioning against automatically applying that conclusion to Ionis Pharmaceuticals’ (IONS) competing program due to differences in the molecules and dosing.</p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col><col><col><col></colgroup><tbody><tr><td>Firm</td><td>Rating Action</td><td>New Target</td><td>Previous Target</td><td>Target Cut</td><td>Upside From Current Levels</td></tr><tr><td>Jefferies</td><td>Maintained 'Buy'</td><td>$28</td><td>$77</td><td>64%</td><td>89%</td></tr><tr><td>TD Cowen</td><td>Maintained 'Buy'</td><td>$18</td><td>$49</td><td>63%</td><td>21%</td></tr><tr><td>Cantor Fitzgerald</td><td>Maintained 'Overweight'</td><td>$33</td><td>$103</td><td>68%</td><td>122%</td></tr><tr><td>Wedbush</td><td>Maintained 'Neutral'</td><td>$23</td><td>$30</td><td>23%</td><td>55%</td></tr><tr><td>RBC Capital</td><td>Cut to 'Sector Perform' from 'Outperform'</td><td>$19</td><td>$40</td><td>53%</td><td>28%</td></tr><tr><td>Canaccord</td><td>Maintained 'Buy'</td><td>$37</td><td>$83</td><td>55%</td><td>149%</td></tr><tr><td>BofA</td><td>Cut to 'Neutral' from 'Buy'</td><td>$20</td><td>$48</td><td>58%</td><td>35%</td></tr><tr><td>Morgan Stanley</td><td>Cut to 'Equal Weight' from 'Overweight'</td><td>$18</td><td>$74</td><td>76%</td><td>21%</td></tr></tbody></table></figure></div><p>TD Cowen called the failure unfortunate but not surprising given already-low expectations. Meanwhile, Jefferies said the outcome was surprising but added that Ultragenyx’s commercial franchise and broader potential was intact. Cantor Fitzgerald said it understood the trial’s risks but had hoped for better results.</p><p>Wedbush removed Apazunersen from its estimates and revised its spending assumptions. Morgan Stanley said the investment debate will now shift toward commercial execution, margin expansion and the remaining pipeline, warning that a strategic reset will take time.&nbsp;</p><h2 class="st-heading-2"><strong>How Do Retail Traders Feel About RARE?</strong></h2><p>On Stocktwits, retail sentiment for RARE jumped to ‘extremely bullish’ from ‘neutral’ levels a week ago amid a 9,200% surge in message volumes over the past week. The ticker’s watcher base has also jumped nearly 40% in a month and 27% in a week.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/rare_ss_4720fba7ea.png" alt="rare ss.png" width="643" height="346"><figcaption>RARE sentiment and message volume as of September 4 | Source: Stocktwits</figcaption></figure><p>One user&nbsp;<a href="https://stocktwits.com/LQQKER_INSIDER/message/663566322">said</a>, “all things considered, the call options appear cheap and I'd say the most prudent way to play this if you want to protect yourselves should it experience another big leg down instead. I'll give this a speculative BUY rating.”</p><p><stembedurl>https://stocktwits.com/LQQKER_INSIDER/message/663566322</stembedurl></p><p>Another user said, “$RARE overreacting. They still generating $740 revenue and have 5 commercialized drugs and q drug to be launched in Q4 and 1 drug has a PDUFA on 9/19/2026. Also, institutional ownership is 128%. This will open &gt;$22|</p><p><stembedurl>https://stocktwits.com/SeniorVip/message/663510523</stembedurl></p><p>RARE stock has declined 53% over the past year.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-nvidia-hugging-face-no-brainer-wall-street-threat-openai-anthropic/cZswMddRJwJ">Michael Burry Calls Nvidia-Hugging Face Deal A ‘No-Brainer’ — Wall Street Sees New Threat For OpenAI And Anthropic&nbsp;</a></p>

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76% and issuing multiple downgrades.

RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout

Ionis Pharmaceuticals Inc

Ultragenyx Pharmaceutical Inc

SPDR S&P Biotech ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$55.96
Prev Close	$54.67
Open	$55.08
Dividend Yield	0.00%
50-Day Moving Average	$62.77
Beta	0.65
Avg. Volume	2M
PE Ratio	147.40

52-Week High	$70.98
52-Week Low	$49.26
Market Capitalization	$10.58B
EPS (Annual)	$1.80
Price to Book	1.67
Revenue Per Employee	$1.01M

Feed

News

Sentiment

Earnings

Fundamentals

Info

BMRN Fundamentals